Table 3.
Cell therapeutic strategy for treating cardiomyopathy.
| Disease Model | Type of Cell Source | Cell Modification | Method of Transplant | Main Outcome | Refs. |
|---|---|---|---|---|---|
| IRI, pig | Human CDC | None | Cell sheet | Reduced infarct size and improved EF | Takehara N. et al. (2008) [99] |
| IRI, mouse | Mouse CPC | Overexpression of APE1/REF1 gene | Intramyocardial injection | Attenuation of fibrosis and improved EF | Aonuma T. et al. (2016) [100] |
| DOX-CM, mouse | Mouse CPC | Delivery of resveratrol into mitochondria | Intramyocardial injection | Reduced oxidative stress of myocardium and longer survival time | Abe J. et al. (2018) [101] |
IRI, Ischemic reperfusion injury; DOX-CM, Doxorubicin-induced cardiomyopathy; CDC, Cardiac derived sphere cell; CPC, Cardiac progenitor cell; APE1/REF1, Apurinic/apyrimidinic endonuclease/redox factor 1; EF, Ejection fraction.